1. A pharmaceutical composition comprising as components: a. methylenetetrahydrofolate, tetrahydrofolate or methyltetrahydrofolate and b. inhibitor, EGFR, for use in treating oncological disease.2. A pharmaceutical composition for use according to Claim. 1, wherein said composition is intended for administration in the absence of 5-ftoruratsila.3. A pharmaceutical composition for use according to Claim. 1, wherein said composition is intended for administration in the absence of analogues, prodrugs and / or metabolites of 5-ftoruratsila.4. A pharmaceutical composition for use according to claim. 2 or 3, wherein the 5-fluorouracil and / or said analogs, prodrugs and / or metabolites of 5-FU is metabolized in FdUMP.5. A pharmaceutical composition for use according to Claim. 1, wherein the treatment is the suppression of cancer growth opuholi.6. A pharmaceutical composition for use according to Claim. 1, wherein the cancer treatment is to reduce the volume opuholi.7. A pharmaceutical composition for use according to claim 1, wherein component b) is selected from EGFR inhibitors listed in Table 1 and gefitinib, erlotinib and lapatinib as well as polyclonal or monoclonal antibodies -. EGFR inhibitors such as cetuximab, panitumumab, zalutumumab, nimotuzumab and matuzumab, or kombinatsiy.8. A pharmaceutical composition for use according to claim. 7, wherein component b) is a monoclonal antibody inhibitor EGFR.9. A pharmaceutical composition for use according to claim. 8, wherein component b) is cetuximab and / or panitumumab.10. A pharmaceutical composition for use according to Claim. 1, wherein component a) is metilentetragidrofolat.11. A pharmaceutical composition for use according to Claim. 1, where com1. Фармацевтическая композиция, содержащая в качестве компонентов:a. метилентетрагидрофолат, тетрагидрофолат или метилтетрагидрофолат иb. ингибитор EGFR,для применения при лечении онкологического заболевания.2. Фармацевтическая композиция для применения по п. 1, где указа
